University of Michigan researchers developed serum albumin-based nanoparticles that delivered plasmid DNA and mRNA into ...
Adding to adjuvant mFOLFOX6 significantly improved outcomes in resected stage III dMMR colon cancer, reducing recurrence or ...
A multicentre study found that an AI model using routine H&E pathology slides and clinicopathological data could estimate genomic recurrence risk and predict chemotherapy benefit in hormone ...
Agilent has received FDA approval for PD-L1 IHC 22C3 pharmDx, Code SK006, as a companion diagnostic to identify patients with esophageal or gastroesophageal junction carcinoma eligible for ...
BioNTech SE will present the latest clinical updates from its late-stage lung cancer portfolio at ELCC 2026, highlighting ...
TG Therapeutics secured $500 million in non-dilutive capital through a new credit facility, supporting the expansion of ...
The FDA has approved nivolumab (Opdivo) plus AVD as first-line treatment for advanced classical Hodgkin lymphoma in patients ...
Phase 3 WU-KONG28 trial met its primary endpoint, showing that once-daily oral sunvozertinib significantly improved ...
A Nature study identifies a previously unknown protein modification, O-2-hydroxyglutarylation, driven by the oncometabolite ...
Vergent Bioscience has launched the Phase 3 VISUALIZE 2 trial evaluating abenacianine, a tumor-activated imaging agent designed to enhance intraoperative tumor detection in lung cancer surgery. The ...
Mayo Clinic has launched the first U.S. clinical research program using magnetic nanoparticle-mediated hyperthermia for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results